PDF(Pubmed)
Abstract：
UNASSIGNED: The aim of this study was to evaluate the effect of the intervention by proactively sharing a patient\'s high polygenic risk score (PRS) for coronary artery disease (CAD). Outcomes included: (i) reduction in cardiovascular disease (CVD) risk factors over 12 months; (ii) difference in purchased prescriptions of lipid-lowering and anti-hypertensive drugs between intervention group and control group subjects; and (iii) opinion of the participating physicians and subjects on PRS usefulness.
UNASSIGNED: This randomized controlled trial was conducted among middle-aged subjects with a top 20% CAD PRS in a family medicine setting. Participants were selected from 26 953 Estonian Biobank cohort participants. Subjects were informed and counselled about their PRS score and CAD risk using the visual tool at baseline (Visit I), counselling session (Visit II), and on the final Visit III at 12 months. The primary endpoint was not significantly different. However, the intervention group participants had a significantly higher probability of initiating statin treatment compared with the controls. Their levels of LDL-cholesterol (LDL-C) were significantly decreased compared with baseline on Visit III and significantly lower than in the control group. The vast majority of participating family physicians believe that finding out about genetic risks will affect the subject\'s lifestyle and medication compliance.
UNASSIGNED: Most of our outcome measures were in favour of this intervention. Participants achieved larger changes in cholesterol and blood pressure values. The vast majority (98.4%) of family physicians are interested in continuing to use genetic risk assessment in practice.
UNASSIGNED: This randomized controlled trial was conducted among middle-aged subjects with a top 20% CAD PRS in a family medicine setting. Participants were selected from 26 953 Estonian Biobank cohort participants. Subjects were informed and counselled about their PRS score and CAD risk using the visual tool at baseline (Visit I), counselling session (Visit II), and on the final Visit III at 12 months. The primary endpoint was not significantly different. However, the intervention group participants had a significantly higher probability of initiating statin treatment compared with the controls. Their levels of LDL-cholesterol (LDL-C) were significantly decreased compared with baseline on Visit III and significantly lower than in the control group. The vast majority of participating family physicians believe that finding out about genetic risks will affect the subject\'s lifestyle and medication compliance.
UNASSIGNED: Most of our outcome measures were in favour of this intervention. Participants achieved larger changes in cholesterol and blood pressure values. The vast majority (98.4%) of family physicians are interested in continuing to use genetic risk assessment in practice.
摘要：
UNASSIGNED：本研究的目的是通过主动分享患者冠状动脉疾病（CAD）的高多基因风险评分（PRS）来评估干预措施的效果。结果包括：（i）12个月内心血管疾病（CVD）危险因素的减少；（ii）干预组和对照组受试者之间购买的降脂和抗高血压药物处方的差异；（iii）参与医师和受试者对PRS有用性的意见。
UNASSIGNED：这项随机对照试验是在家庭医学环境中CADPRS最高20％的中年受试者中进行的。从26953名爱沙尼亚生物银行队列参与者中选择参与者。在基线时使用视觉工具告知受试者并咨询他们的PRS评分和CAD风险(访问I),咨询会议（访问II），并在12个月的最后一次访问III。主要终点没有显著差异。然而,与对照组相比,干预组参与者开始他汀类药物治疗的概率明显较高.在第III次访问时，他们的LDL-胆固醇（LDL-C）水平与基线相比显着降低，并且显着低于对照组。绝大多数参与的家庭医生认为，了解遗传风险会影响受试者的生活方式和药物依从性。
未经评估：我们的大多数结果指标都支持这种干预措施。参与者获得了更大的胆固醇和血压值变化。绝大多数（98.4％）的家庭医生对在实践中继续使用遗传风险评估感兴趣。
UNASSIGNED：这项随机对照试验是在家庭医学环境中CADPRS最高20％的中年受试者中进行的。从26953名爱沙尼亚生物银行队列参与者中选择参与者。在基线时使用视觉工具告知受试者并咨询他们的PRS评分和CAD风险(访问I),咨询会议（访问II），并在12个月的最后一次访问III。主要终点没有显著差异。然而,与对照组相比,干预组参与者开始他汀类药物治疗的概率明显较高.在第III次访问时，他们的LDL-胆固醇（LDL-C）水平与基线相比显着降低，并且显着低于对照组。绝大多数参与的家庭医生认为，了解遗传风险会影响受试者的生活方式和药物依从性。
未经评估：我们的大多数结果指标都支持这种干预措施。参与者获得了更大的胆固醇和血压值变化。绝大多数（98.4％）的家庭医生对在实践中继续使用遗传风险评估感兴趣。
